Article Text

Download PDFPDF
Randomised controlled trial
Oral treatment of acute pulmonary embolism with a fixed dose of rivaroxaban is non-inferior to standard treatment

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Competing interests AN has received lecture fees from Boehringer Ingelheim, served on an advisory board for Boehringer Ingelheim and received travel fees from Boehringer Ingelheim, Daiichi Sankyo and Pfizer.